HLA Profiling: Enhancing Precision in Immunopeptidomics and Immunotherapy

In the rapidly evolving field of precision immunotherapy, HLA profiling plays a pivotal role in understanding how peptides are presented to the immune system. By mapping peptide–HLA interactions across diverse alleles and tissues, researchers can predict immune responses with greater accuracy — a cornerstone for developing safer and more effective therapies.
At Alithea Bio, our expertise lies in HLA immunopeptidomics, combining mass spectrometry, bioinformatics, and AI-driven analytics to identify naturally presented peptides. This high-resolution profiling enables us to explore the immunopeptidome — the complete set of peptides bound to HLA molecules — providing insights into epitope presentation, off-target risk assessment, and neoantigen discovery.
Accurate HLA profiling helps uncover which peptides are most stably presented, guiding antigen prioritization for:

Immunotherapy target validation
Neoantigen and biomarker discovery
Off-target toxicity prediction
Personalized vaccine development
Our proprietary HLA-Compass platform integrates multi-omics data to analyze millions of peptides, linking immunopeptidomics data with biological relevance. This approach not only supports cancer vaccine development but also advances the understanding of immune safety in biologics and therapeutic proteins.
As highlighted in our keyword analysis, improving visibility for terms like immunopeptidomics database, HLA peptide analysis, immunopeptidomics workflow, and off-target toxicity prediction is essential to reaching scientific audiences searching for data-driven immunotherapy solutions. Through continuous HLA profiling and peptide analytics, Alithea Bio is shaping the next generation of precision immunopeptidomics for translational research and drug discovery.